CAMDERO

This brand name is authorized in Estonia

Active ingredients

The drug CAMDERO contains a combination of these active pharmaceutical ingredients (APIs):

1 Candesartan
UNII R85M2X0D68 - CANDESARTAN CILEXETIL

Candesartan is an AIIRA, selective for AT1 receptors, with tight binding to and slow dissociation from the receptor. It has no agonist activity. The antagonism of the angiotensin II (AT1) receptors results in dose related increases in plasma renin levels, angiotensin I and angiotensin II levels, and a decrease in plasma aldosterone concentration.

Read about Candesartan
2 Amlodipine
UNII 864V2Q084H - AMLODIPINE BESYLATE

Amlodipine is a calcium ion influx inhibitor of the dihydropyridine group (slow channel blocker or calcium ion antagonist) and inhibits the transmembrane influx of calcium ions into cardiac and vascular smooth muscle.

Read about Amlodipine

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code Group title Classification
C09DB07 C Cardiovascular system → C09 Agents acting on the renin-angiotensin system → C09D Angiotensin II antagonists, combinations → C09DB Angiotensin II antagonists and calcium channel blockers
Discover more medicines within C09DB07

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country Identification scheme Identifier(s)
Country: EE Ravimiamet Identifier(s): 1732092, 1732104, 1732115, 1732126, 1732137, 1732148, 1732159, 1732160, 1732171, 1732182, 1732193, 1732205, 1732216, 1732227, 1732238, 1732249, 1732250, 1732261, 1732272, 1732283, 1732294, 1732306

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈